哺乳动物细胞色素P450 在大肠杆菌上表达的研究进展

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (9): 970-973.

哺乳动物细胞色素P450 在大肠杆菌上表达的研究进展

张澈^1,2, 张志权¹, 周宏灏²

¹湖北省郧阳医学院附属太和医院药学部, 十堰442000, 湖北;
²中南大学临床药理研究所, 长沙410083, 湖南

收稿日期:2007-04-23 修回日期:2007-08-07 出版日期:2007-09-26 发布日期:2020-10-30
通讯作者: 周宏灏, 男, 博士生导师, 中国工程院院士, 主要从事临床药理学和遗传药理学研究。Tel:0731-4805380 E-mail:hhzhou@public.cs.hn.cn
作者简介:张澈, 男, 硕士, 主管药师, 主要从事临床药理学和药物毒副作用监测。Tel:0719-6761945 E-mail:kjj80116@yahoo.com.cn
基金资助:
国家自然科学基金项目(30371668)

Advancement of mammalian CYP450s expression in E.coli

ZHANG Che^1,2, ZHANG Zhi-quan¹, ZHOU Hong-hao²

¹Pharmacy Department, Affiliated Taihe Hospital of Yun Yang Medical College, Shiyan 442000, Hubei, China;
²Pharmacogenemics Research Institute, Institute of Clinical Pharmacology, Central SouthUniversity, Changsha 410078, Hunan, China

Received:2007-04-23 Revised:2007-08-07 Online:2007-09-26 Published:2020-10-30

摘要/Abstract

摘要： 细胞色素P450(cytochrome P450, CYP450) 是人体内代谢各种内外源性物质最重要的酶系之一。随着分子生物学和重组技术的飞跃发展, 对哺乳动物来源的CYP450 cDNA 进行精细操作并将使其在异源系统中表达成为可能。目前已经有多种异源系统被用来进行哺乳动物CYP450 的表达, 每一种系统都各具优缺点。哺乳动物CYP450 在大肠杆菌上的表达是在实验室中的主要表达方式, 但采用不同的方式表达的蛋白量不一样, 而且对蛋白酶的活性也有着一定的影响;同时, 蛋白纯化手段的选择也会影响CYP450 表达方式的应用。本文拟对哺乳动物CYP450 在大肠杆菌上的表达纯化现状和应用进行概述。

关键词: 异源表达, 细胞色素P450, 大肠杆菌

Abstract: Cytochrome P450(CYP450) is one of most important enzymes to metabolize endogenous and exogenous substrates in vivo.With the development of molecular biology and recombinant technology, the manipulating and heterogeneous expression of CYP450 cDNA become possible.Many kinds of heterogeneous expression systems have been generally operated nowadays, of which there are advantages and disadvantages respectively.It is usual to express mammalian CYP450s using E.coli as host in Lab, but different protein production and enzyme activity are brought by different expression systems and purification procedures.The present application of different expression modes using E.coli for mammalian CYP450 cDNA will be introduced as well as their advantages and the limits respectively.

Key words: heterogeneous expression, cytochrome P450, E.coli

中图分类号:

R968

张澈, 张志权, 周宏灏. 哺乳动物细胞色素P450 在大肠杆菌上表达的研究进展[J]. 中国临床药理学与治疗学, 2007, 12(9): 970-973.

ZHANG Che, ZHANG Zhi-quan, ZHOU Hong-hao. Advancement of mammalian CYP450s expression in E.coli[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(9): 970-973.

参考文献

1 Zhu LQ, Lou JS.Resent studies on cytochrome P450 and drug metabolism [J].Chin J Clin Pharmacol Ther, 2004;9:1081-1084.
2 Friedberg T, Pritchard MP, BanderaM, et al.Merits and limitations of recombinant models for the study of human p450-mediated drug metabolism and toxicity :an intra-laboratory comparison [J].Drug Metab Rev, 1999;31:523-544.
3 Sandhu P, Baba T, Guenguerich FP.Expression of modified cytochrome P450 2C10 (2C9) in Echerichia coli, purification, and reconstitution of catalytic activity [J].Arch Biochem Biophys, 1993;306:443-450.
4 Larson JR, CoonMJ, Porter TD.Alcohol-inducible cytochrome P-450IIE1 lacking the hydrophobic NH2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli [J].J Biol Chem, 1991;266 :7321-7324.
5 Larson JR, Coon MJ, Porter TD.Purification and properties of a shortened form of cytochrome P-450 2E1:Deletion of the NH2-terminal membrane-insertion signal peptide does not alter the catalytic activities [J].Proc Nati Acad Sci USA, 1991;88: 9141-9145.
6 Li YC, Chiang JY.The expression of a catalytically active cholesterol 7α-hydroxylase cytochrome P450 in Escherichia coli [J]. J Biol Chem, 1991;266:19186-19191.
7 Loomanl AC, Bodlaender J, Comstock LJ, et al.Influence of the codon following the AUG initiation codon on the expression of a modified lacZ gene in Escherichia coli [J].EMBO J, 1987; 6:2489-2492.
8 Barnes HJ, Arlotto MP, Waterman MR.Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli [J].Prc Natl Acad Sci USA, 1991;88:5597-5601.
9 Shet MS, Fisher CW, Ariotto MP, et al.Purification and enzymatic properties of a recombinant fusion protein expressed in Escherichia coli containing the domains of bovine P450 17A1 and rat NADPH-P450 reductase [J].Arch Biochem Biophys, 1993; 311:402-417.
10 Guo Z, Gillam EMJ, Ohmod S, et al.Expression of modified human eytochrome P450 1AI in Escherichia coli :effects of 5'substitution, stabilization, purification, spectral characterization and catalytic properties [J].Arch Biochem Biophys, 1994; 312:436-446.
11 Sandhu P,Guo Z, Baba T, et al.Expression of modified human cytochrome P450 IA2 in Escherichla coil:stabilization, purification, spectral characterization, and catalytic activities of the enzyme [J].Arch Biochem Biophys, 1994;309:168-177.
12 Kranendonk M, Fisher CW, Roda R, et al.Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 :comparison of three types expression systems [J].Mutat Res, 1999;439 :287-300.
13 Kranendonk M, Carreira F, Theisen P, et al.Escherichia coli · 972 · Chin J Clin Pharmacol Ther 2007 Sep;12(9) MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5:catalytic activities and mutagenicity studies [J].Mutat Res, 1999;441:73-83.
14 Gillam EMJ, Baba T, Kim B-R, et al.Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconsitition of the enzyme [J].Arch Biochem Biophys, 1993;305 :123-131.
15 Gillam EM, Wunsch RM, Ueng YF, et al.Expression of cytochrome P450 3A7 in Escheriachia coli :ffects of 5'-modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase [J].Arch Biochem Biophys, 1997;346:81-90.
16 Palmer CNA, Richardson TH, Griffin KJ, et al.Characterization of a cDNA coding a human kidney, cytochrome P-450 4A fatty acid omega-hydroxylase and the cognate enzyme expressed in Escherichia coli [J].Biochim Biophy s Acre Gene Struct, 1993; 1172 :161-166.
17 Andersen JF, Utermohlen JG, Feyereisen R.Expression of house fly CYP6A1 and NADPH.cytochrome P450 reductase in Escherichia coli and reconstitution of an insecticide-metabolizing P450 system [J].Biochemistry, 1994;33 :2171-2177.
18 Fisher CW, Caudle DL, Martin-Wixtrom C, et al.High-level expression of functional human cytochrome P450 1A2 in Escherichia coli [J].FASEB J, 1992;6:759-764.
19 Shet MS, Fisher CW, Holmans PL, et al.Human cytochrome P450 3A4:Enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase [J].Proc Natl Acad Sci USA, 1993;90:11748-11752.
20 Shet MS, Fisher CW, Ariotto MP, et al.Purification and enzymatic properties of a recombinant fusion protein expressed in Escherichia coli containing the domains of bovine P450 17A1 and rat NADPH-P450 reductase [J].Arch Biochem Biophys, 1994;377:402-417.
21 Blake JAR, Pritchard M, Ding SH, et al.Co-expression of a human P450 (CYP3A4) and P450 reductase generates a highly functional mono-oxygenase system in Escherichia coli [J].FEBS Lett, 1996;397:210-214.
22 Parikh A, Guengerich FP.Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2 :rat NADPH-cytochrome P450 reductase fusion protein [J].Protein Expr Purif, 1997;9:346-354.
23 Kamataki T, Fujita K, Nakayama K, et al.Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives:application of genetically engineered Salmonella expressing human CYP [J].Drug Metab Rev, 2002;34:667-676.
24 Gillam EMJ, Baba T, Kim BR, et al.Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme [J].Arch Biochem Biophys, 1993;305:121-131.
25 Zhuang X, Zhang H.Identification, characterization of levoglucosan kinase, and cloning and expression of levoglucosan kinase cDNA from Aspergillus niger CBX-209 in Escherichia coli [J]. Protein Expr Purif, 2002;26:71-81.
26 Domanski TL, Finta C, Halpert JR, et al.cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450 [J].Mol Pharmacol, 2001;59 :386-392.
27 Zhou JQ, Tang ZQ.Cytochrome P450 directed prodrug activation therapy in research of cancer enzymology [J].J Chin Pharmace Sci, 2005;14 :1-9.
28 Friedberg I.Recombinant in vitro tools to predict drug metabolism and safety [J].Pharm Sci Technolo Today, 2000;3:99-105.

[1]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[2]	吴懿, 方芳, 陈瑛, 樊军卫. 供受体CYP3A5基因型对肝移植术后早期他克莫司谷浓度的影响作用及其临床意义[J]. 中国临床药理学与治疗学, 2021, 26(6): 631-639.
[3]	吴茂锋, 刘畅, 戴慧晖, 麦长凤, 黄丹丽, 缪经纬, 刘丽忠, 方翼. pazopanib血药浓度个体差异与细胞色素P450 3A4基因多态性的关系初探[J]. 中国临床药理学与治疗学, 2020, 25(12): 1376-1380.
[4]	彭秋菊，严华成，石磊. 细胞色素P450 SNP与冠心病易感性关系的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(4): 477-480.
[5]	肖鹏，梅家转，白桦，栗敏，刘桂举，李瑞君，沈杰. 细胞色素P450 1A1基因多态性对奥沙利铂联合卡培他滨方案治疗结直肠癌患者临床疗效的影响[J]. 中国临床药理学与治疗学, 2018, 23(2): 159-164.
[6]	张培玉，任静，职文倩，刘澄铭，郜娜. 和厚朴酚等五种中药有效成分对CYP酶活性的体外抑制作用[J]. 中国临床药理学与治疗学, 2017, 22(8): 922-926.
[7]	刘晶晶, 梁智, 罗详冲, 何功浩, 冯恩富, 徐贵丽. LC-MS/MS法同时测定大鼠血浆中4种CYP450探针药物浓度[J]. 中国临床药理学与治疗学, 2017, 22(2): 144-150.
[8]	韦艺丹，许美娟，季晖. 花生四烯酸的ω-羟化代谢途径与心脑血管疾病[J]. 中国临床药理学与治疗学, 2016, 21(7): 826-833.
[9]	贾元威，沈杰，谢海棠，黄锐. 天麻素对人肝微粒体细胞色素P450酶的抑制作用[J]. 中国临床药理学与治疗学, 2016, 21(2): 134-138.
[10]	殷硕, 于月, 郭兴蕾, 刘高峰. 中药对华法林作用的影响及机制概述[J]. 中国临床药理学与治疗学, 2015, 20(3): 327-334.
[11]	阳喜定，阳国平，黄洁，谭鸿毅. NF-κB对细胞色素P450调控作用机制研究进展[J]. 中国临床药理学与治疗学, 2015, 20(11): 1302-1307.
[12]	戴海将, 李莹, 文佳, 袁洪, 刘梅林. 细胞色素P450在高血压发生及个体化治疗中的研究进展[J]. 中国临床药理学与治疗学, 2015, 20(10): 1165-1170.
[13]	刘丽雅, 韩永龙, 余奇, 朱金辉, 郭澄. 消癌平注射液等4种抗肿瘤中药注射剂对人肝微粒体中CYP450酶7种亚型的体外抑制作用研究[J]. 中国临床药理学与治疗学, 2014, 19(5): 522-527.
[14]	刘俊, 栾家杰, 徐文科, 朱艳虹, 汪魏平, 张大发. 中国汉族人群基于临床特征和基因型华法林个体化给药模型的研究[J]. 中国临床药理学与治疗学, 2014, 19(3): 284-290.
[15]	章冉冉, 阳国平, 荆宁宁, 黄洁, 黄路, 王艳. 食物对细胞色素P450药物代谢酶的影响[J]. 中国临床药理学与治疗学, 2014, 19(2): 200-205.